The Effect of Cladribine Tablets on Brain Volume over 4 Years in the MAGNIFY-MS Extension Study
Barkhof F, Schmierer K, Vermersch P, et al.
Poster: P687
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Barkhof F
Impact of Cladribine Tablets on GFAP Levels and Intrathecal Biomarkers in RMS: Results from the MAGNIFY-MS Study
Wiendl H, Derfuss T, Sponton L, et al.
Poster: P1694
Session: ePoster
Date: September 24-26, 2025
Presenter: Wiendl H
Long-Term Effect of Cladribine Tablets on Disability Progression and Improvement: Insights from Pooled Analyses of CLARIFY-MS and MAGNIFY-MS Studies
Vermersch P, Wiendl H, Leocani L, et al.
Poster: P335
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Vermersch P
Cladribine Tablets Show Low 4-Year PIRA Rates in MS: Insights from Pooled Analyses of CLARIFY-MS and MAGNIFY-MS Studies
Montalban X, De Stefano N, Hodgkinson S, et al.
Poster: P1707
Session: ePoster
Date: September 24-26, 2025
Presenter: Montalban X
Comparing Changes in Brain Tissue Damage Between the Two-year Active Dosing Treatment Period and the Following Two Years Extension Period in Cladribine-treated MS Patients Stratified by MRI Phenotypes
De Stefano N, Sforazzini F, Luchetti L, et al.
Poster: P208
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: De Stefano N
Cladribine Tablets-treated Multiple Sclerosis Patients Show Different Spatio-temporal Patterns of Acute, Chronic and Resolving Brain Inflammatory Activity
Gentile G, Smyk A, Ben-Amor A-F, et al.
Poster: P1450
Session: ePoster
Date: September 24-26, 2025
Presenter: Gentile G
Using Deep Learning on Baseline MRI Data for Highly Accurate Prediction of Cladribine Tablets-treated MS Patients who Improve Physical and Cognitive Disability in 4 Years
Battaglini M, Sforazzini F, Luchetti L, et al.
Poster: P672
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Battaglini M
Incidence Rate of Malignancies in People with Multiple Sclerosis Newly Initiating Cladribine Tablets or Fingolimod: Second Interim Results from CLARION
Glaser A, Ziemssen T, Butzkueven H, et al.
Poster: P856
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Glaser A
Real-world Experience with Cladribine (Mavenclad) in the MSBase Registry 2025
Spelman T, van der Walt A, Ozakbas S, et al.
Poster: P875
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Butzkueven H
Treatment Continuation With Cladribine Tablets Beyond Year 4: Analysis of Longitudinal Prescription Data From Germany
Kormann D, Parekh M, von der Maßen K, et al.
Poster: P1773
Session: ePoster
Date: September 24-26, 2025
Presenter: Kormann D
Real-world Experience with Cladribine Tablets in Older Age Groups in the MSBase Registry
Spelman T, van der Walt A, Havrdova E, et al.
Poster: P1985
Session: ePoster
Date: September 24-26, 2025
Presenter: Butzkueven H
Cladribine Tablets Reduce Pathological Brain Ageing Gap in MS Patients
Leoncini M, Battaglini M, Sforazzini F, et al.
Poster: P432
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Leoncini M
Clinical Outcomes of Cladribine Tablets in Aging (≥50 years) Patients with Relapsing Multiple Sclerosis in a Real-World Setting: Insights From the ‘Aging’ Study
Katz J, Hughes B, Gutierrez A, et al.
Poster: P332
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Katz J
Relationship Between CSF Cellular Populations and MRI Biomarkers of MS Disease Severity: Insights from the CLOCK-MS Study
Samara A, Judge B, Salter A, et al.
Poster: P1471
Session: ePoster
Date: September 24-26, 2025
Presenter: Brier MR
Three-Year Effectiveness and Safety Data for Cladribine Tablets in Patients with Relapsing Multiple Sclerosis after Transitioning from Natalizumab (CLADRINA Study)
Sguigna P, Okai A, Kaplan J, et al.
Poster: P1947
Session: ePoster
Date: September 24-26, 2025
Presenter: Sguigna P
Treatment Continuation with Cladribine Tablets (CladT) Beyond Year 4– Second Interim Analysis of the CLIP-5 Study
Korsukewitz C, Richter N, Klehmet J, et al.
Poster: P1803
Session: ePoster
Date: September 24-26, 2025
Presenter: Korsukewitz C
Long-term Effects of Treatment with Cladribine Tablets on Cognition and Treatment Satisfaction in People with Relapsing Multiple Sclerosis: 4‑year Results from the Noninterventional CLADQoL Study
Penner I-K, Chudecka A, Refik P, et al.
Poster: P1820
Session: ePoster
Date: September 24-26, 2025
Presenter: Penner I-K
48 Month Follow-up of Maven4: a Phase IV Non-interventional, Prospective, Spanish Multicenter Study to Assess the Long Term Effectiveness of Cladribine Tablets in Real-world Clinical Practice
Aladro-Benito Y, Costa-Frossard L, Sánchez Magro MI, et al.
Poster: P346
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Aladro-Benito Y
Design and Baseline Characteristics of the Real-world MAVENAGE Study in Relapsing MS Patients Older and Younger Than 50 Years Treated with Cladribine Tablets
Meca-Lallana JE, Eichau S, Oreja-Guevara C, Meca V, et al.
Poster: P1649
Session: ePoster
Date: September 24-26, 2025
Presenter: Meca-Lallana JE
Retrospective Analysis of Multiple Sclerosis Patients Who Initiated Oral Cladribine 5-8 Years Ago – Data from a German Cladribine Cohort
Woitschach L, Cepek L, Kowarik M, et al.
Poster: P357
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Ernst M
Clinical Effectiveness of Cladribine Tablets for PwMS Switching from Natalizumab, AntiCD20 Treatment or “Other”; Data from the Swedish Post-market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 10” (IMSE 10)
Forsberg L, Larsson V, Hillert J, et al.
Poster: P1762
Session: ePoster
Date: September 24-26, 2025
Presenter: Forsberg L
Clinical Effectiveness and Safety of Cladribine Tablets for PwMS Treated at Least 36 Months in the Swedish Post-market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 10” (IMSE 10)
Forsberg L, Larsson V, Hillert J, et al.
Poster: P344
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Forsberg L
Clinical Effectiveness of Cladribine Tablets for Patients Below or Above 50 Years of Age at Treatment Start in the Swedish Post-market Surveillance Study “Immunomodulation and Multiple Sclerosis Epidemiology 10” (IMSE 10)
Larsson V, Forsberg L, Hillert J, et al.
Poster: P861
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Larsson V
CLADCOMS – CLADribine Tablets Long-term Control of MS – a Post-Marketing Investigator Driven Study
Larsson V, Forsberg L, Nilsson P, et al.
Poster: P865
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Larsson V
Clinical Effectiveness of Cladribine Tablets for Patients with Few vs Many Treatments Prior CladT Initiation in the CLADCOMS Study -CLADribine Tablets Long-term Control Of MS – a Post-marketing Investigator Driven Study
Larsson V, Forsberg L, Nilsson P, et al.
Poster: P1804
Session: ePoster
Date: September 24-26, 2025
Presenter: Larsson V
Recurrent Effects on the Clonal Composition of Peripheral B Cells in MS Patients During the Second Year of Cladribine Treatment
Tieck MP, Vasilenko N, Stadelmaier J, et al.
Poster: P813
Session: Poster Session 2
Date: September 25, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Tieck MP
Preliminary Data of Paramagnetic Rim Lesion Dynamic at 7 Tesla Magnetic Resonance Imaging in Cladribine Tablets-Treated People with Multiple Sclerosis
Dal-Bianco A, Hametner S, Grabner G, et al.
Poster: P216
Session: Poster Session 1
Date: September 24, 2025
Time: 07:30-09:30 am PDT/10:30 am-12:30 pm EDT
Presenter: Dal-Bianco A
Baseline and Early Safety Data Following Full Recruitment of ChariotMS, the First DMT trial for People with Advanced MS (EDSS 6.5-8.5)
Schmierer K, Mattoscio M, De Angelis F, et al.
Poster: P1633
Session: ePoster
Date: September 24-26, 2025
Presenter: Schmierer K
Breaking Inflammatory Cycles: Cladribine Targets Pathogenic B Cell Subsets in Multiple Sclerosis
Pirronello M, Picozza M, Corbisiero S, et al.
Poster: P1374
Session: ePoster
Date: September 24-26, 2025
Presenter: Battistini L
Circulating MicroRNAs as Potential Biomarkers for Treatment Response in Cladribine-Treated Multiple Sclerosis Patients
Vigiser I, Zeevi Y, Piura Y, Kolb H, Golan M, Karni A, Regev K
Poster: P762
Session: ePoster
Date: September 24-26, 2025
Presenter: Vigiser I
Integrin β1 Demarks Circulating Precursors of Brain-residing Antibody-secreting Cells in People with MS
Kuiper K, Bogers L, Rip J, et al.
Oral presentation: O123
Session: Scientific Session 14: Antibody-mediated pathology
Date: September 26, 2025
Time: 12:26-12:33 am PDT/03:26-03:33 am EDT
Presenter: Smolders J
Early Lymphocyte Reduction as a Potential Marker of Cladribine Efficacy
Celius E, et al.
Poster: P2028
Session: ePoster
Date: September 24-26, 2025
Presenter: Celius E